Healthy Life Agritec Limited reported a standalone net profit of ₹74.35 lakh for the quarter ended June 30, 2026 (Q1FY27), compared to ₹47.52 lakh in the corresponding period of FY26. While the company achieved significant top-line growth, profitability metrics indicated margin compression during the period.

Total income for the quarter stood at ₹2,840.99 lakh, marking a substantial increase from ₹1,667.70 lakh recorded in Q1FY26. This represents a year-on-year revenue growth of approximately 70%. However, total expenses rose to ₹2,739.27 lakh from ₹1,603.98 lakh in the prior year, outpacing the revenue growth rate and impacting the bottom line.

Financial Performance Overview

The company’s pre-tax profit before exceptional and extraordinary items was ₹101.73 lakh, down from ₹121.89 lakh in Q4FY26 and up from ₹63.71 lakh in Q1FY26. The post-tax net profit for the current quarter reflects a decline when compared to the immediately preceding quarter, where it stood at ₹85.25 lakh.

Earnings per share (EPS) for the quarter were ₹0.15 (basic) and ₹0.25 (diluted), compared to basic EPS of ₹0.19 and diluted EPS of ₹0.20 in the same quarter last year.

What the Numbers Show

A key divergence in the financials is the disparity between revenue growth and expense management. While revenue surged by over 70% year-on-year, total expenses increased by roughly 71%, leading to a slight contraction in operating leverage. The net profit after tax declined by approximately 25% compared to Q1FY26, despite the significant top-line expansion. This suggests that the cost structure did not scale efficiently with the higher sales volume during the quarter.

Additionally, the equity share capital remained unchanged at ₹4,962.40 lakh, indicating no fresh equity raises or buybacks during the period. The figures for the previous period have been regrouped or reclassified where necessary, as per accounting standards.

Regulatory Approvals

The Board of Directors of Healthy Life Agritec Limited approved the unaudited financial results for the quarter ended June 30, 2026, at a meeting held on August 14, 2026. The results have been reviewed by the Audit Committee and filed with the stock exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The detailed financial results are available on the company’s website and the BSE India portal.

Healthy Life Agritec Ltd reported a consolidated net profit of ₹399.54 lakh for the year ended March 31, 2026, an increase from ₹325.56 lakh in the previous year. Revenue from operations for the period rose to ₹22,814.20 lakh, compared to ₹17,187.06 lakh in FY25. The company's board approved the audited standalone and consolidated financial results on June 8, 2026, following a delay attributed to the late receipt of financial statements from a subsidiary.

The statutory auditors, NYS & Company, issued an unmodified opinion on the financial results. However, the audit report highlighted key matters, including non-compliance with Tax Deducted at Source (TDS) regulations and Employees' Provident Fund and Employees' State Insurance provisions. The company also reported outstanding undisputed income tax liabilities and noted that the Internal Audit Report and Report on Internal Financial Control were not available for verification at the time of the report.

Financial Performance

For the standalone financial results, the company reported a net profit of ₹245.50 lakh for FY26, up from ₹186.77 lakh in the previous year. Revenue from operations stood at ₹10,707.20 lakh. Earnings per share (EPS) on a basic basis for the year stood at ₹0.49, compared to ₹0.75 in the prior year, impacted by the expansion of the equity base.

During the year, the company raised ₹2,481.20 lakh through a rights issue of 24,812,000 equity shares with a face value of ₹10 each. The funds were primarily utilized for working capital requirements and general corporate purposes, with no deviation from the stated objects as monitored by Care Ratings Limited.

Consolidated Results Summary

The company confirmed that the delay in filing the results was neither intentional nor deliberate, reaffirming its commitment to timely compliance with Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.